United States real-world studies highlight the importance of controlling lupus nephritis to improve patient prognosis.

Greater disease activity and higher proteinuria levels were associated with a greater risk for VTE among patients with LN.

The results of the ALLEGORY trial of Gazyva (obinutuzumab) suggest that the anti-CD20 antibody could have broad utility in ...

These findings underscore the limitations of relying on proteinuria alone to assess LN treatment success and demonstrate the clinical utility of biomarker-guided risk stratification.

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

The FDA has approved Gazyva (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.

"Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

The FDA has approved Gazyva (obinutuzumab) for treating adult patients with active lupus nephritis who are already on ...

AJMC ®: What measures can be taken to enhance comprehensive screening efforts for the early diagnosis of lupus nephritis in patients who have systemic lupus erythematosus? How do you screen for lupus ...

This transcript has been edited for clarity. Matthew A. Sparks, MD: I'm Dr Matthew Sparks, and welcome to Medscape's InDiscussion podcast series on chronic kidney disease. Today we'll be discussing ...